Szentirmay Zoltán, Veleczki Zsuzsa, Kásler Miklós
Országos Onkológiai Intézet Budapest, Ráth György u. 7-9., 1122.
Orv Hetil. 2017 Aug;158(31):1213-1221. doi: 10.1556/650.2017.30807.
Persistent infection of human papillomavirus is known to cause cervical intraepithelial neoplasia or cancer in the cervix uteri and other HPV-associated cancers in different localization. Based on epidemiological and biological data, principally the high risk HPV is responsible for development of cervical these cancers. However, we have no information about the frequently distribution of different HPV types and what is the correlation between the HPV types and cytological diagnosis in cervical intraepithelial neoplasia (CIN).
In this paper, we are going to present new data involving incidence and mortality of HPV-associated cancers during the period of 2009-2015 in Hungary. We are also going to investigate the correlation of cervical cytological diagnosis and HPV typing, and the preventive effect of HPV vaccination.
The epidemiological data spring from the National Cancer Registry. HPV typing was performed by Linear Array HPV Genotyping Test. Simultaneous cytological diagnosis and HPV typing was carried out on 2048 cytological samples collected in period of 2009-2016.
According to the epidemiologic data, the most frequently occurring HPV-associated cancer is the laryngeal carcinoma in man, and the cervical cancer in woman in Hungary. During the 2009-2015 time intervals, the frequency distribution of head and neck cancers was not changed in man, but the incidence of tongue root squamous cell carcinomas was gradually increasing in woman. We have defined the clinical significance of single and simultaneously multiple HPV infection and have investigated the correlation of the HPV frequency distribution and cytological diagnosis in CIN. It was found that in the cytological negativity of probably/possibly carcinogen pHR-HPV group classified by IACR was much more frequent as in HR-HPV group (56% versus 47%). The presence of simultaneous multiplex HPV infection betokens an increased cancer risk. According to the international publications, the ratio of HPV16 just twice as big as in cervical cancer, what we found in CIN (60% versus 30%). The frequency order of the HPV18 is 2nd in cancer, and 9th in CIN. Comparing the frequency distribution of HR/pHR-HPVs in cervical cancer and CIN, the HR-HPV35 is very rarely occurring in CIN, the pHR-HPV56, 66, and 73 is more frequently seen in CIN as in carcinoma. Appreciated the preventive value of anti-HPV vaccines, we have found a significant differences in group with 1 HPV/sample and in group with more than 1 HPV/sample.
The frequency distribution of tongue root squamous cell carcinoma and cervical cancer was gradually increasing in woman. The overall preventive effect of 9-valent vaccine is 80.3%. This preventive value should be higher because of the transformation ability of the different HPV types is not same. Out of consideration for HPV incidence in cancer, the preventive effect of 9-valent or 4-valent vaccines might reach to 93% or 73%. However, the pHR-HPVs are biologically active, it is not sufficient for the inclusion of these HPV types into population-wide HPV-DNA based cervical screening programs. Orv Hetil. 2017; 158(31): 1213-1221.
已知人乳头瘤病毒的持续感染会导致子宫颈上皮内瘤变或子宫颈癌以及不同部位的其他与HPV相关的癌症。基于流行病学和生物学数据,主要是高危型HPV导致了这些子宫颈癌的发生。然而,我们并不了解不同HPV类型的常见分布情况以及HPV类型与子宫颈上皮内瘤变(CIN)细胞学诊断之间的相关性。
在本文中,我们将呈现2009年至2015年期间匈牙利HPV相关癌症的发病率和死亡率的新数据。我们还将研究子宫颈细胞学诊断与HPV分型之间的相关性以及HPV疫苗的预防效果。
流行病学数据源自国家癌症登记处。通过线性阵列HPV基因分型检测进行HPV分型。对2009年至2016年期间收集的2048份细胞学样本同时进行细胞学诊断和HPV分型。
根据流行病学数据,在匈牙利,最常见的HPV相关癌症在男性中是喉癌,在女性中是子宫颈癌。在2009年至2015年期间,男性头颈癌的频率分布没有变化,但女性舌根鳞状细胞癌的发病率逐渐上升。我们确定了单一和同时多重HPV感染的临床意义,并研究了CIN中HPV频率分布与细胞学诊断之间的相关性。发现在国际癌症研究机构(IARC)分类的可能/潜在致癌性pHR-HPV组的细胞学阴性情况比高危型HPV组更常见(56%对47%)。同时多重HPV感染的存在预示着癌症风险增加。根据国际出版物,HPV16的比例在子宫颈癌中是我们在CIN中发现的两倍(60%对30%)。HPV18的频率在癌症中排第二,在CIN中排第九。比较子宫颈癌和CIN中HR/pHR-HPVs的频率分布,HR-HPV35在CIN中非常罕见,pHR-HPV56、66和73在CIN中比在癌中更常见。认识到抗HPV疫苗的预防价值,我们发现在每样本1种HPV的组和每样本1种以上HPV的组之间存在显著差异。
女性舌根鳞状细胞癌和子宫颈癌的频率分布逐渐上升。9价疫苗的总体预防效果为80.3%。由于不同HPV类型的转化能力不同,这种预防价值应该更高。考虑到癌症中HPV的发病率情况,9价或4价疫苗的预防效果可能达到93%或73%。然而,pHR-HPVs具有生物学活性,将这些HPV类型纳入基于人群的HPV-DNA子宫颈筛查项目是不够的。《匈牙利医学周报》。2017年;158(31):1213 - 1221。